Cargando…
Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers
Platinum drugs and PARP inhibitors (“PARPis”) are considered to be effective in BRCA-associated cancers with impaired DNA repair. These agents cause stalled and collapsed replication forks and create double-strand breaks effectively in the absence of repair mechanisms, resulting in arrest of the cel...
Autores principales: | Yamamoto, Kimiyo N., Hirota, Kouji, Takeda, Shunichi, Haeno, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144917/ https://www.ncbi.nlm.nih.gov/pubmed/25158060 http://dx.doi.org/10.1371/journal.pone.0105724 |
Ejemplares similares
-
Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors
por: Imyanitov, Evgeny, et al.
Publicado: (2021) -
The Epistatic Relationship between BRCA2 and the Other RAD51 Mediators in Homologous Recombination
por: Qing, Yong, et al.
Publicado: (2011) -
The evolution of tumor metastasis during clonal expansion with alterations in metastasis driver genes
por: Yamamoto, Kimiyo N., et al.
Publicado: (2015) -
Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
por: Le, Bac Viet, et al.
Publicado: (2022) -
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
por: Pishvaian, Michael J, et al.
Publicado: (2017)